NEW YORK, March 28 (GenomeWeb News) - Proteomics company Power3 Medical Products and New Horizons Diagnostics plan to use Power3's protein biomarkers to co-develop antibody-based diagnostics for neurodegenerative diseases, the firms said today.
Power3 said it will develop a series of tests that monitor the concentration of panels of proteins in the blood. The company said it has discovered 34 biomarkers whose profiles are "relatively sensitive and specific" in distinguishing patients with amyotrophic lateral sclerosis, Alzheimer's, and Parkinson's disease from each other, from patients with other neuromuscular and neurological disorders, and from controls.
Through its deal with New Horizons Diagnostics, Power3 is "now positioned to take our biomarkers into the high throughput immunodiagnostic test market," the company said in a statement.
Specifically, New Horizons will employ monoclonal and polyclonal antibodies to the biomarkers, which will be incorporated into immunoassays, the firms said. Once the assays are available, New Horizons Diagnostics will develop and validate diagnostic tests on its platform that is specifically designed to detect and discriminate among the neurodegenerative diseases.